EBMT 2019 | Molecular techniques for monitoring MRD in AML
Torsten Haferlach
Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
2:31
The structure of ERIC 2020 and the workshops available
Paolo Ghia
1:28
Why young scientists should attend ERIC 2020
Kostas Stamatopoulos
1:44
Immunoglobulins and microenvironmental triggers in CLL pathogenesis
Kostas Stamatopoulos
0:59
Successes of ERIC and the change to virtual congress
Paolo Ghia
1:10
The pathways of CLL pathogenesis and CLL’s relationship with MBL
Kostas Stamatopoulos
